Abbott CEO Says Barron's 'Got It Totally Wrong' On Nutrition Spinoff, Calls It A Move From Strength

Robert Ford defended the planned nutrition separation on the earnings call, then took questions on a sales-guidance cut and infant-formula litigation.

Share
Abbott CEO Says Barron's 'Got It Totally Wrong' On Nutrition Spinoff, Calls It A Move From Strength

Abbott Chairman and CEO Robert Ford said on the company's third-quarter earnings call that the planned spinoff of its nutrition business is "coming out of a position of strength," and he said a Barron's headline on the plan "got it totally wrong." The business has approximately $8.5 billion in annual sales and would separate through a tax-free distribution to Abbott shareholders.

What Ford said about the spinoff

Ford told a JPMorgan analyst he had read the Barron's headline that morning. "I'm just going to say it," he said, repeating that the move comes from strength. He cited nutrition's volume growth this quarter, which he said is well above its peer set.

He said he chose the phrase "battle tested" for the nutrition team because that is "what it felt like over the last four or five years."

On why spin rather than sell, Ford said a sale would carry tax costs and a timeline Abbott does not fully control. He said Abbott has no interest in selling.

On sequencing, Ford said Abbott has to weigh the organization's bandwidth to absorb moves, and he put the spin after the Exact Sciences deal. He said Abbott entered nutrition more than 60 years ago and that the market has shifted from one shaped by healthcare professionals toward one shaped by consumer preferences and retail execution.

Nutrition would have 16,000 employees and 14 manufacturing sites. Ford said Daniel Salvadori, now Executive Vice President and Group President of Established Pharmaceuticals and Nutrition Products, will become its CEO. Ford said he expects it to qualify for the S&P 500.

The numbers behind the plan

CFO Phil Boudreau said Abbott expects to finish the separation by the end of next year, subject to approvals. Removing nutrition would speed Abbott's sales growth by 50 to 100 basis points, he said. Gross margin would rise by more than 200 basis points and operating margin by about 100 basis points.

The new company plans to raise debt and send part of the proceeds to Abbott. Boudreau said the amounts and the final share distribution ratio will come later. The two companies' dividends combined are expected to equal Abbott's dividend at the time of the separation.

Separation costs will be excluded from adjusted earnings, Boudreau said.

The litigation and guidance questions

An analyst at Wells Fargo asked whether the infant-formula liability stays with Abbott. Ford did not say. He said resolving the litigation is not a prerequisite for the separation and that he would detail where the liability sits later.

He said Abbott took a "meaningful step" in August by settling 2,000 claimants, but that the settlement does not change its position that it stands behind the products' safety and efficacy.

The same analyst asked about the full-year sales guidance cut. Ford said it implies fourth-quarter growth of just over 8% and blamed electrophysiology and diabetes. He said the electrophysiology headwind from the left atrial appendage market should be about five points of growth, putting that business near 20% in the fourth quarter, down from about 25%. He expects diabetes growth in a low-to-mid single-digit range for the next few quarters.

For 2027, Ford said he would start with sales guidance "pretty similar to this year" and give formal guidance on the January call. Abbott reported adjusted earnings per share of $1.42 in the third quarter and forecast $1.62 to $1.67 for the fourth. In Wednesday trading, shares were at $99.74, down about 3% from the prior close.

Abbott's January call will carry 2027 guidance, and Ford said the share distribution ratio and the new company's debt plans will come before the separation.

Sources

More on Abbott Laboratories

All Abbott Laboratories (ABT) coverage →